Moleculin Biotech (NASDAQ:MBRX) posted its quarterly earnings data on Thursday. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03, Zacks reports.
Shares of Moleculin Biotech stock opened at $0.60 on Friday. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.02. Moleculin Biotech has a 52-week low of $0.32 and a 52-week high of $3.15. The company has a 50-day simple moving average of $0.70 and a two-hundred day simple moving average of $0.96.
MBRX has been the topic of several research reports. ValuEngine raised shares of Moleculin Biotech from a “hold” rating to a “buy” rating in a research note on Thursday, February 6th. Zacks Investment Research lowered shares of Moleculin Biotech from a “hold” rating to a “sell” rating in a research note on Saturday, February 22nd. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $2.50.
Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.